<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced immune thrombocytopenia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced immune thrombocytopenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced immune thrombocytopenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald M Arnold, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam Cuker, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unexplained thrombocytopenia is a common clinical problem, and the possibility of drug-induced thrombocytopenia must be considered, especially in hospitalized patients, in whom new drugs are commonly administered. Drugs can cause thrombocytopenia by several mechanisms including direct bone marrow or other organ toxicity. Many of the cytotoxic drugs used for cancer chemotherapy and other conditions produce dose-dependent reductions in platelet counts due to bone marrow suppression as a known effect of the drug.</p><p>This topic review discusses drug-induced immune thrombocytopenia (DITP), in which the mechanism involves antibody-mediated platelet destruction caused by exposure to a drug that leads to isolated thrombocytopenia (without anemia or leukopenia). The "drug" in this context may be a prescribed medication (or its metabolite), over-the-counter medicine, herbal supplement, food, beverage, or other substance. </p><p>Other types of drug-induced thrombocytopenia are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Heparin-induced thrombocytopenia (HIT) – (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced thrombotic microangiopathy (DITMA) – (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p>General approaches to evaluating patients with thrombocytopenia in various settings are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonates – (See  <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Children – (See  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Adults – (See  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy – (See  <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pancytopenia – (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombotic microangiopathy – (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="headingAnchor" id="H1439334316"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>We use the following terminology/definitions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudothrombocytopenia</strong> – Pseudothrombocytopenia is a laboratory artifact in which the patient is not thrombocytopenic; apparent thrombocytopenia is due to platelet clumping in the collection tube due to an in vitro reaction with the anticoagulant. The finding is confirmed by repeating the platelet count using a fresh sample and/or reviewing the peripheral blood smear. Typically, a sample for a repeat platelet count is drawn into a tube containing an anticoagulant other than EDTA (eg, citrate). (See  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'Pseudothrombocytopenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Thrombocytopenia is defined as a platelet count below the lower limit of normal (&lt;150,000/microL). Some individuals will have a stable platelet count that may be slightly lower than this value and is normal for that individual; these individuals may not require additional testing or intervention. Conversely, some individuals may have a platelet count above the lower limit of the reference interval that represents a significant decrease from baseline for that individual; in such cases it is prudent to repeat the platelet count in one or two days to determine if there is a declining trend. (See <a class="local">'Approach'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary immune</strong> <strong>thrombocytopenia</strong> – Primary immune thrombocytopenia (ITP) is an autoimmune phenomenon with no apparent underlying cause. (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced immune thrombocytopenia</strong> – Drug-induced immune thrombocytopenia (DITP), the focus of this topic review, refers to thrombocytopenia caused by drug-dependent antibody-mediated platelet destruction. DITP is a form of secondary ITP. The "drug" in this context may be a prescribed medication (or its metabolite), over-the-counter medicine, herbal supplement, food, beverage, or other substance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-immune drug-induced thrombocytopenia</strong> – Many drugs used as chemotherapy cause thrombocytopenia by bone marrow suppression. <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> is an example. Some drugs have a combined mechanism that includes drug-dependent antibodies and bone marrow suppression. (See <a class="local">'Mechanisms of DITP'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin-induced thrombocytopenia</strong> – Heparin-induced thrombocytopenia (HIT) is a unique drug reaction in which antibodies against complexes of platelet factor 4 and heparin cause both thrombocytopenia and platelet activation, resulting in venous and/or arterial thrombosis. Patients with suspected HIT require immediate institution of a non-heparin anticoagulant. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF DITP</span><span class="headingEndMark"> — </span>Thrombocytopenia in DITP is caused by accelerated platelet (and rarely, megakaryocyte) destruction from drug-dependent, platelet-reactive antibodies [<a href="#rid1">1-3</a>]. In almost all cases, drug-dependent antiplatelet antibodies bind non-covalently to specific platelet antigens via their Fab regions. DITP with megakaryocyte destruction from drug-dependent antibodies has been described for <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a> [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a> has been the most widely studied drug to determine the mechanism of DITP; quinine can also cause drug-induced thrombotic microangiopathy (DITMA). Quinine-dependent antibodies may be derived from a pool of naturally occurring antibodies that are weakly reactive with autologous proteins, such as platelet surface glycoproteins [<a href="#rid5">5-7</a>]. Quinine, and possibly other drugs causing DITP, can become integrated into complementarity-determining regions of these naturally occurring antibodies, creating a hybrid paratope (modified antigen-binding region) that greatly increases the antibody’s binding affinity to platelet surface antigens  (<a class="graphic graphic_figure graphicRef130247" href="/z/d/graphic/130247.html" rel="external">figure 1</a>) [<a href="#rid6">6,8</a>]. The phenomenon of naturally occurring antibodies may explain the observation of extremely rapid platelet count drop with some drugs such as GP IIb/IIIa inhibitors (see <a class="local">'GP IIb/IIIa inhibitors'</a> below). In DITP caused by abciximab, antibodies to murine (mouse) antigens may be responsible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another potential mechanism is that binding of the drug to the platelet surface can cause a conformational change in a surface protein that leads to exposure of a neoepitope, which in turn stimulates the formation of antiplatelet antibodies [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-dependent antibodies may have specificity for major drug metabolites as well as (or instead of) the parent drug. In a study of sulfamethoxazole-induced thrombocytopenia, 10 antibodies that reacted with intact sulfamethoxazole also reacted strongly with the N1-acetyl metabolite [<a href="#rid10">10</a>]. Similar results have been obtained with <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid11">11</a>]. Reactions that occur exclusively with a metabolite (but not the parent drug) may explain the common occurrence of negative results with drug-dependent antibody testing [<a href="#rid10">10</a>]. Examples include <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, for which drug-dependent, platelet-reactive antibodies have only been identified for drug metabolites and not for the parent drug [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-dependent antibodies typically do not cross-react with different drugs that have a similar molecular structure (eg, they react to sulfamethoxazole but not to the nearly identical sulfisoxazole, or to <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> but not the optical stereoisomer <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>) [<a href="#rid10">10,12</a>]. This may support the use of other drugs in the same class in patients with a history of DITP; however, unless the antibody specificity (and lack of cross-reactivity) is known for that particular patient, we generally do not assume other drugs of the same class will be safe. (See <a class="local">'Role of drug-dependent platelet antibody testing'</a> below and <a class="local">'Role of drug rechallenge'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some drugs can cause acute, immune-mediated thrombocytopenia mediated by drug-dependent antibodies in addition to causing bone marrow suppression. Well-documented examples are <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid13">13,14</a>]. In some cases multiple drug-dependent antibodies are produced [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other drugs can precipitate immune-mediated thrombocytopenia in which thrombocytopenia begins or continues even after the drug is stopped. Gold, which was previously used to treat certain types of arthritis, had been classically implicated in causing this syndrome. Other examples include <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> and immune checkpoint inhibitors such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid16">16</a>]. In one report, 6 of 216 patients developed severe thrombocytopenia 1 to 15 months following the last dose of alemtuzumab [<a href="#rid17">17</a>]. The thrombocytopenia was responsive to traditional treatment for ITP, which resulted in prolonged remissions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccines are another example.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children, the measles-mumps-rubella (MMR) vaccine has also been associated with thrombocytopenia that has the clinical characteristics of primary ITP [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ITP has also been reported following administration of certain coronavirus disease 2019 (COVID-19) vaccines, though causation has not been definitively established [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to chemotherapy drugs traditionally recognized as cytotoxic to the bone marrow, some other commonly used drugs can cause moderate, but relatively specific suppression of platelet production in the bone marrow. Examples include <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a>, and <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> [<a href="#rid20">20-22</a>]. </p><p></p><p>Platelet antigens that are targeted by drug-dependent antibodies may include a variety of surface glycoproteins, most commonly GP Ib/V/IX or GP IIb/IIIa. Others may also be involved (eg, GP V, platelet-endothelial cell adhesion molecule-1 [PECAM-1]). Some antibodies may bind to multiple regions of a single glycoprotein or to multiple epitopes simultaneously [<a href="#rid9">9,23-26</a>].</p><p class="headingAnchor" id="H2637212144"><span class="h1">COMMONLY IMPLICATED DRUGS</span></p><p class="headingAnchor" id="H2503311283"><span class="h2">List of drugs</span><span class="headingEndMark"> — </span>Commonly implicated drugs and their mechanism of thrombocytopenia are listed in the table  (<a class="graphic graphic_table graphicRef73618" href="/z/d/graphic/73618.html" rel="external">table 1</a>) [<a href="#rid1">1,11,27-35</a>]. A database of drugs associated with DITP, updated approximately every two years, is available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ouhsc.edu%2Fplatelets&amp;token=ZiLQ8BkqDz0AL92cCSR%2BAYrPaP%2Fj2cBcvuhigIEBe4reUe5gp2QPsBE7BNRIM9z%2F&amp;TOPIC_ID=6674" target="_blank">www.ouhsc.edu/platelets</a> [<a href="#rid36">36</a>]. The database also includes information updated annually from Versiti Blood Center of Wisconsin on drug-dependent platelet-reactive antibodies.</p><p>A 2013 systematic review of DITP that considered both clinical and laboratory criteria for the diagnosis of DITP, including the documentation of drug-dependent platelet antibodies by at least two different laboratories, found the following drugs to be directly implicated in DITP reactions: <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, penicillin, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">suramin</a>, GP IIb/IIIa inhibitors, and heparin [<a href="#rid37">37</a>]. </p><p>Other drugs have been implicated because they have been identified as causing DITP by three different methods: (i) case reports with definite evidence, (ii) identification of drug-dependent antibodies, (iii) data mining of the US Food and Drug Administration's Adverse Event Reporting System database [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H4015238257"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The overall risk of DITP from any new drug is rare. The absolute incidence depends on the patient population; individuals who are hospitalized are more likely to receive new drugs, including antibiotics, and to have a higher incidence of DITP than healthy outpatients. </p><p class="bulletIndent1"><span class="glyph">●</span>Review articles summarizing epidemiologic data suggest a population incidence of 10 per million population [<a href="#rid2">2,38,39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of DITP have been reported with specific drugs:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a> – 38 per million</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> – 26 per million</p><p class="bulletIndent2"><span class="glyph">•</span>GPIIb/IIIa inhibitors – 1 to 2 percent (first exposure); as high as 10 percent (second exposure to abciximab [no longer available in the United States])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates have also been reported in patients in the intensive care unit (ICU) [<a href="#rid39">39</a>]. A report of 329 patients in the ICU found thrombocytopenia in 41 percent; of these, 9 percent were attributed to a drug [<a href="#rid40">40</a>]. Other common causes in the ICU include sepsis, liver disease, hypersplenism, and disseminated intravascular coagulation (DIC). (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'Acutely ill/intensive care unit'</a>.)</p><p></p><p class="headingAnchor" id="H1386204"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The typical patient history includes one or more medications, herbal remedies, foods, beverages, or other substances known to cause DITP. The interval between initiation of a new drug taken daily and DITP is usually less than two weeks. A drug taken daily for several months or longer is rarely associated with DITP. Drugs taken only intermittently may cause DITP even if it has been many years since the previous exposure [<a href="#rid2">2</a>]. The following features define the typical clinical presentation, which can be used to determine the likelihood of DITP.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient age</strong> – Drug-induced thrombocytopenia may be less common in children than adults [<a href="#rid41">41</a>]. In a 2013 systematic review of case reports limited to children, 32 substances were identified with a definite or probable causal role in thrombocytopenia [<a href="#rid41">41</a>]. Implicated drugs included antibiotics (<a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>), antiepileptics (<a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>), and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – In the typical presentation of DITP, the drop in platelet count occurs within two weeks of exposure to the drug. As an example, in a series of 12 patients with thrombocytopenia associated with <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>, the median interval was 6.5 days of initial continuous exposure [<a href="#rid42">42</a>]. Another report described 13 patients exposed to abciximab in whom thrombocytopenia developed after an interval of three to six days [<a href="#rid43">43</a>]. If the patient has been sensitized by a previous exposure to the drug, the onset of thrombocytopenia may be more rapid (eg, as early as hours after exposure). Thrombocytopenia due to a GP IIb/IIIa inhibitor may occur within the first 24 hours of the initial exposure and can occur after minutes to hours (see <a class="local">'GP IIb/IIIa inhibitors'</a> below). There are rare reports of thrombocytopenia caused by <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or piperacillin occurring with the first day of exposure, but previous sensitizing exposure may have occurred in these patients [<a href="#rid30">30,42</a>]. The previous exposure may have been in an unusual form, such as vancomycin in orthopedic cement [<a href="#rid44">44</a>]. It has also been speculated that a previous exposure may have occurred due to the presence of antibiotics in foods, but we are unaware of data to support this [<a href="#rid42">42</a>]. As noted below, most patients with DITP have prompt platelet count recovery upon drug discontinuation and a normal platelet count by one week. (See <a class="local">'Platelet count recovery/monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of thrombocytopenia</strong> – The thrombocytopenia in DITP is often severe, with a nadir platelet count &lt;20,000/microL [<a href="#rid28">28,42,45</a>]. An exception is heparin-induced thrombocytopenia (HIT), in which the median nadir platelet count is approximately 60,000/microL and platelet counts &lt;20,000/microL are rare [<a href="#rid46">46</a>]. (See <a class="local">'Heparins'</a> below and  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Thrombocytopenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likely drugs</strong> – As described above, DITP has been associated with a number of drugs; the typical history involves a drug with high-quality evidence for causing DITP including laboratory demonstration of drug-dependent immunoglobulin binding to platelets in vitro in two or more independent cases  (<a class="graphic graphic_table graphicRef73618" href="/z/d/graphic/73618.html" rel="external">table 1</a>) [<a href="#rid37">37</a>]. (See <a class="local">'Commonly implicated drugs'</a> above.)</p><p></p><p>In most cases, the only associated clinical or laboratory findings in patients with drug-induced thrombocytopenia are those related to thrombocytopenia or bleeding. These may include petechiae, purpura, mucosal bleeding (eg, epistaxis), and/or more serious bleeding. Bleeding risk and prevention is discussed below. (See <a class="local">'Treatment of bleeding/severe thrombocytopenia'</a> below.)</p><p class="headingAnchor" id="H1667814489"><span class="h1">SPECIAL CASES</span></p><p class="headingAnchor" id="H441347681"><span class="h2">Heparins</span><span class="headingEndMark"> — </span>Heparins, including both <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and low molecular weight (LMW) heparins such as <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> and <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a>, can cause heparin-induced thrombocytopenia (HIT). HIT is a type of antibody-mediated drug-induced thrombocytopenia, but because of its distinct characteristics (eg, platelet activation and risk of thrombosis), we do not include it in our discussion of DITP. Diagnosis and management of HIT are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H3919567145"><span class="h2">GP IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>Glycoprotein (GP) IIb/IIIa inhibitors (eg, abciximab, <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a>, <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a>) are used in patients with coronary heart disease or coronary stenting. All patients receiving a GP IIb/IIIa inhibitor should have a baseline platelet count prior to drug initiation, and platelet count monitoring during and after treatment, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p>These drugs can be associated with the rapid onset of DITP (minutes to hours after exposure), often profound, with an incidence on the order of 1 to 4 percent [<a href="#rid47">47-53</a>]. The rapid onset is thought to be explained by the presence of preformed, "naturally occurring" antibodies, especially with abciximab [<a href="#rid2">2,54-57</a>]. Their mechanism of causing thrombocytopenia (eg, opsonization, platelet activation, or both) is unclear [<a href="#rid58">58</a>]. (See <a class="local">'Mechanisms of DITP'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abciximab</strong> – In a review of four large randomized trials, the incidence of true thrombocytopenia with abciximab was found to be 3.7 percent (205 of 5476 patients), compared with 1.8 percent (56 of 3079) in those assigned to placebo [<a href="#rid53">53</a>]. In patients receiving placebo, thrombocytopenia would have been due to another drug or non-drug cause. Another pooled analysis that evaluated data from eight randomized trials involving GP IIb/IIIa inhibitors found abciximab-induced thrombocytopenia in 5.2 percent, of which most were considered mild (platelet count &lt;90,000 to 100,000/microL) [<a href="#rid51">51</a>]. The incidence of severe thrombocytopenia (&lt;50,000/microL) was 1 percent with abciximab versus 0.4 percent with placebo.</p><p></p><p class="bulletIndent1">Antibodies in abciximab-associated DITP recognize murine peptide sequences incorporated into the abciximab Fab fragment that confer specificity for GP IIb/IIIa [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">Eptifibatide</a> – In a pooled analysis that evaluated data from eight randomized trials involving GP IIb/IIIa inhibitors, eptifibatide was not associated with an increased incidence of thrombocytopenia [<a href="#rid51">51</a>]. The incidence of thrombocytopenia was not increased with eptifibatide in the PURSUIT trial (eptifibatide versus placebo in 10,948 patients with acute coronary syndrome) [<a href="#rid60">60</a>]. Although eptifibatide-induced thrombocytopenia may be less common than thrombocytopenia induced by abciximab and <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a>, the occurrence and mechanism have been reported [<a href="#rid58">58</a>]. In addition to causing thrombocytopenia, eptifibatide can also activate platelets resulting in thrombosis [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">Tirofiban</a> – The incidence of thrombocytopenia was increased with tirofiban in the PRISM trial (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus tirofiban versus aspirin plus heparin in 3232 patients with unstable angina); rates were 1.1 percent with tirofiban and 0.4 percent with heparin [<a href="#rid61">61</a>]. However, in a pooled analysis that evaluated data from eight randomized trials involving GP IIb/IIIa inhibitors, tirofiban was not associated with an increased incidence of thrombocytopenia [<a href="#rid51">51</a>].</p><p></p><p>The GP IIb/IIIa inhibitors are also associated with an increased incidence of pseudothrombocytopenia, a laboratory artifact of no clinical importance [<a href="#rid48">48</a>]. A review of four large randomized trials found the incidence of pseudothrombocytopenia associated with abciximab to be approximately 2 percent (117 of 5476 patients), compared with 0.6 percent (17 of 3079) assigned to placebo [<a href="#rid53">53</a>]. The anticoagulant in the sample collection tube was EDTA in most of the 117 cases, although 14 were documented to occur in the presence of citrate also. The presumed mechanism of EDTA-induced platelet agglutination is thought to involve naturally occurring antiplatelet antibodies that recognize EDTA-induced conformational changes in platelet GP IIb/IIIa.</p><p>Our approaches to distinguishing between true thrombocytopenia and pseudothrombocytopenia, and between thrombocytopenia due to a GP IIb/IIIa inhibitor, heparin, or another cause, is presented below. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1979264223"><span class="h2">Approach</span><span class="headingEndMark"> — </span>Overall, the risk of DITP from any new drug is low [<a href="#rid45">45</a>]. However, among patients with thrombocytopenia, it is important to assess the possibility of DITP as the cause because this diagnosis has major implications for management. DITP should be suspected in a patient who presents with new onset of thrombocytopenia, especially sudden unexpected thrombocytopenia or recurrent episodes of acute thrombocytopenia without an obvious etiology.</p><p>DITP is a clinical diagnosis made by excluding other causes of thrombocytopenia and documenting resolution of thrombocytopenia upon drug discontinuation. Recurrent acute episodes of thrombocytopenia after drug re-exposure is strongly suggestive of DITP. Laboratory testing for drug-dependent antiplatelet antibodies is helpful if the result is positive, but false-negative results are common and the turnaround time for the test is generally long, as testing is only done in reference laboratories. (See <a class="local">'Role of drug-dependent platelet antibody testing'</a> below.)</p><p>If the patient has had previous occurrence of thrombocytopenia with previous exposure to the suspected drug, this further supports the diagnosis. Re-exposures should generally be avoided due to the risks of causing recurrent, severe thrombocytopenia and bleeding. (See <a class="local">'Role of drug rechallenge'</a> below.)</p><p>The patient evaluation is focused on identifying clues to other possible diagnoses and determining the likelihood of these other diagnoses versus DITP. For patients receiving multiple drugs, close evaluation of the timing of the drug exposure and the likelihood of DITP for each drug is especially valuable. (See <a class="local">'Medication review/temporal relationship'</a> below.)</p><p class="headingAnchor" id="H419607675"><span class="h2">Confirm thrombocytopenia</span><span class="headingEndMark"> — </span>As with any case of unexpected thrombocytopenia, the possibility of laboratory error or pseudothrombocytopenia (ie, in vitro artifact) should be addressed before conducting an extensive evaluation or stopping a needed medication. This is done by examining the peripheral blood smear for platelet clumping  (<a class="graphic graphic_picture graphicRef68949" href="/z/d/graphic/68949.html" rel="external">picture 1</a>) and repeating the platelet count. In vitro platelet clumping can occur due to incomplete mixing of the sample, or to an interaction with the anticoagulant in the sample collection tube. This is especially true for EDTA (the routine anticoagulant employed for blood counts). Appropriate alternative sample tubes include those containing citrate or heparin as the anticoagulant in the tube.</p><p>Review of the blood smear is essential for eliminating other possible diagnoses such as an inherited platelet disorder or a thrombotic microangiopathy such as thrombotic thrombocytopenic purpura (TTP). (See <a class="local">'CBC and blood smear review'</a> below.)</p><p>A significant drop in platelet count (eg, by 50 percent or more) is sufficient to trigger review of the blood smear, more intensive platelet count monitoring, or other interventions, even if the platelet count is ≥150,000/microL. The frequency of accelerated monitoring depends on the absolute platelet count, rate of decline, and suspected diagnoses. As examples, such a drop in platelet count in a patient receiving a heparin product or a GP IIb/IIIa inhibitor may be the first indication of heparin-induced thrombocytopenia (HIT) or DITP, respectively. In suspected HIT, heparin is immediately discontinued, a non-heparin anticoagulant initiated, and platelet count monitored daily until it begins to recover. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H2498910334"><span class="h2">Exclude other causes of thrombocytopenia</span><span class="headingEndMark"> — </span>The likelihood of other possible causes of thrombocytopenia  (<a class="graphic graphic_table graphicRef77063" href="/z/d/graphic/77063.html" rel="external">table 2</a>) depends on the clinical setting (eg, incidental finding in an asymptomatic individual seen as an outpatient, or an acutely ill patient in hospital) [<a href="#rid42">42</a>]. For all patients it is important to assess the complete blood count (CBC) for other abnormalities and review all possible drug exposures, with close attention to the temporal relationship between drug exposure and platelet count decrease.</p><p class="headingAnchor" id="H930238521"><span class="h3">Clues from the patient history and clinical setting</span></p><p class="headingAnchor" id="H3634581192"><span class="h4">Incidental finding</span><span class="headingEndMark"> — </span>An otherwise healthy patient may have thrombocytopenia as an incidental finding on a CBC performed for other reasons, or may develop thrombocytopenia in association with a self-limited illness. Other common causes of isolated thrombocytopenia in asymptomatic patients include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral infection</p><p class="bulletIndent1"><span class="glyph">●</span>Primary immune thrombocytopenia (ITP)</p><p class="bulletIndent1"><span class="glyph">●</span>Previously unrecognized inherited platelet disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Myelodysplastic syndrome (MDS), especially in older patients; however, MDS rarely presents with isolated thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Nutrient disorder such as vitamin B12 or folate deficiency, although other cytopenias often are present and folate deficiency is extremely rare in countries that use routine folate supplementation in foods</p><p></p><p>In some cases, these alternative causes may be distinguished from drug-induced thrombocytopenia by findings on the peripheral blood smear such as abnormal platelet size or granulation (for inherited disorders) or megaloblastic changes (for MDS or nutrient disorders). Other distinguishing factors are discussed below and in separate topic reviews. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H953522658"><span class="h4">Acutely ill or hospitalized patient</span><span class="headingEndMark"> — </span>Acutely ill or hospitalized patients may have thrombocytopenia as a result of their underlying illness or its treatment. Other common causes of thrombocytopenia in acutely ill patients include sepsis, acute infection, and/or disseminated intravascular coagulation (DIC). Post-transfusion purpura is often associated with severe bleeding, but it is very rare. Nevertheless, DITP should be considered in any hospitalized patient who develops thrombocytopenia during an acute illness or in the hospital.</p><p>Thrombocytopenia in combination with thrombosis is especially concerning because it raises the possibility of HIT (see <a class="local">'Determine if the patient was exposed to heparin'</a> below) or other serious conditions including antiphospholipid syndrome (APS), paroxysmal nocturnal hemoglobinuria (PNH), or a thrombotic microangiopathy (TMA). These conditions require special interventions and expertise.</p><p>Early input from the consulting specialist is advised. </p><p class="headingAnchor" id="H140710522"><span class="h3">CBC and blood smear review</span><span class="headingEndMark"> — </span>For all patients, it is important to review the CBC and peripheral blood smear because other abnormalities (cytopenias, morphologic features) may suggest an alternate or additional diagnosis. Examples of important findings that suggest a diagnosis other than drug-induced thrombocytopenia include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancytopenia</strong> – Pancytopenia (anemia, leukopenia, and thrombocytopenia) suggests the possibility of aplastic anemia (which could also be drug-induced) or another bone marrow disorder. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Drugs'</a> and  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microangiopathic hemolytic anemia</strong> – The combination of microangiopathic hemolytic anemia (MAHA; suggested by the presence of schistocytes on the peripheral blood smear) and thrombocytopenia in the setting of drug exposure suggests drug-induced thrombotic microangiopathy (DITMA) or another type of TMA. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet morphologic abnormalities</strong> – Platelet abnormalities such as giant platelets or platelets that lack granules may suggest an inherited platelet disorder. However, not all inherited thrombocytopenias are associated with abnormal platelet morphology. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other CBC findings</strong> – Additional abnormalities on the CBC may suggest an infectious cause (eg, intracellular parasites, white blood cell findings consistent with infection) or a primary bone marrow disorder (eg, megaloblastic changes, immature granulocytes). Evaluation for these conditions is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2779908509"><span class="h3">Medication review/temporal relationship</span><span class="headingEndMark"> — </span>Establishing a clear temporal relationship between initiation of a drug and development of thrombocytopenia is essential, although this may be challenging.</p><p>A patient with recurrent episodes of acute thrombocytopenia should be suspected of having a drug-induced etiology because the intermittent nature of the thrombocytopenia may correspond to intermittent exposure or ingestion of a food, beverage, or herbal remedy [<a href="#rid62">62</a>]. In addition to the timing of drug ingestion, it is important to take a thorough history and consult lists of commonly implicated drugs. (See <a class="local">'Commonly implicated drugs'</a> above.)</p><p>A detailed history must address all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Prescribed drugs</p><p class="bulletIndent1"><span class="glyph">●</span>Over-the-counter medications such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative medicines, folk remedies, and herbal preparations [<a href="#rid63">63,64</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Recent vaccinations </p><p class="bulletIndent1"><span class="glyph">●</span>Medications prescribed by other physicians</p><p class="bulletIndent1"><span class="glyph">●</span>Medications prescribed for family members or other individuals, which the patient may not want to admit to taking</p><p class="bulletIndent1"><span class="glyph">●</span>Certain common beverages associated with thrombocytopenia such as tonic water (which contains <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>) [<a href="#rid62">62,65</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Foods, such as walnuts and tahini [<a href="#rid62">62,66,67</a>]</p><p></p><p>Explicit questioning is essential because patients commonly assume that when doctors ask about medications, they are only asking about prescribed medications that are taken regularly [<a href="#rid68">68,69</a>]. As an example, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> is perhaps the most common cause of drug-induced thrombocytopenia, and it is often overlooked in the patient’s history [<a href="#rid68">68,70</a>]. Quinine tablets are only available by prescription in the United States, but can be obtained over-the-counter in Canada and other countries. Quinine is also an ingredient of beverages (eg, tonic water, bitter lemon)  (<a class="graphic graphic_table graphicRef60296" href="/z/d/graphic/60296.html" rel="external">table 3</a>). Quinine is also used for its fluorescent properties in party drinks such as "jello shots" and "shocktails" [<a href="#rid65">65</a>]. A variety of foods and other substances have been associated with acute, immune-mediated thrombocytopenia [<a href="#rid62">62,67</a>].</p><p>Most drugs require prior sensitization, either through daily administration or administration at a previous time. However, some drugs may cause thrombocytopenia at the initial exposure without prior sensitization. This commonly occurs with the glycoprotein IIb/IIIa inhibitors (eg, abciximab, <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a>, <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a>), and has also been seen with other drugs, such as <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a> [<a href="#rid30">30,42</a>]. In some cases there may have been a previous exposure that was unrecognized [<a href="#rid44">44</a>], as discussed above. (See <a class="local">'Clinical presentation'</a> above.)</p><p class="headingAnchor" id="H3023115879"><span class="h3">Determine if the patient was exposed to heparin</span><span class="headingEndMark"> — </span>Heparin-induced thrombocytopenia (HIT) is a unique drug reaction that carries a risk of potentially fatal thrombosis. Heparin discontinuation alone is insufficient to reduce this risk, and the patient must be treated with a non-heparin anticoagulant. While some patients present with thromboses, many do not, and the absence of thrombosis does not exclude HIT.</p><p>Heparin exposure is most likely in hospitalized patients but may also occur in outpatients who are receiving injections of low molecular weight (LMW) heparin. Hospitalized patients may have received heparin at the time of an invasive procedure or in heparin flushes, heparin bonded catheters, or some plasma products such as certain prothrombin complex concentrates (PCCs) [<a href="#rid71">71</a>]. In such cases, the medication record may not list heparin as a regular medication. It is thus especially important to review the possibility of heparin administration, and to estimate the likelihood of HIT and the need for more extensive testing and presumptive treatment with a non-heparin anticoagulant while awaiting results of this testing. Estimation of pretest probability of HIT is presented separately. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Stop heparin for a presumptive diagnosis of HIT'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Decide which drug(s) to stop</span><span class="headingEndMark"> — </span>The decision to stop a medication is straightforward for a healthy outpatient who develops new onset thrombocytopenia within one or two weeks of starting a new medication for which evidence for causing thrombocytopenia is already available  (<a class="graphic graphic_table graphicRef73618" href="/z/d/graphic/73618.html" rel="external">table 1</a>). If a drug is discontinued and the platelet count improves, this supports the diagnosis of DITP due to that drug [<a href="#rid72">72</a>]. (See <a class="local">'Platelet count recovery/monitoring'</a> below.)</p><p>However, the decision of which drug(s) to stop, if any, may be more challenging in other settings, especially in hospitalized patients who are often receiving multiple medications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-medication substance/intermittent exposure</strong> – A non-medication substance such as a food or beverage, an over-the-counter herbal product, or a medication taken intermittently may be responsible in a healthy outpatient who has recurrent/intermittent episodes of thrombocytopenia but denies taking any regular medications. In some cases, the patient may disclose taking an herbal product or medication available over-the-counter or prescribed for another individual on further questioning. In others, the patient may be able to identify a food or beverage such as tonic water, which contains <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> (see <a class="local">'Medication review/temporal relationship'</a> above). These substances can then be discontinued and the platelet count observed. The role of rechallenge to confirm the diagnosis is discussed below. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug not previously implicated in causing thrombocytopenia</strong> – In a patient who is prescribed a drug not previously known to cause thrombocytopenia, the importance of continuing the medication must be balanced with the likelihood that the drug versus another diagnosis such as ITP is responsible. If the clinical scenario is compatible with DITP, the drug should be stopped and testing for drug-dependent antiplatelet antibodies should be done (see <a class="local">'Management'</a> below). A negative test does not exclude the diagnosis, but a positive test supports the diagnosis. Of note, it is important to report newly identified causes of DITP to the appropriate monitoring agency. (See <a class="local">'Documentation/reporting'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple medications/hospitalized patient</strong> – Several confounding factors may make it difficult to determine whether a drug has caused thrombocytopenia in a patient who is acutely ill or hospitalized, and if so, which drug is most likely to be responsible [<a href="#rid42">42</a>]. Some drugs may be given once, and as a result they no longer appear in the medication charting, and it may be necessary to review other records (eg, anesthesia record) or speak with nursing staff and the patient. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It may be possible that thrombocytopenia is a result of the underlying illness. This is especially likely in a patient with an acute infection or sepsis [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If multiple drugs have been administered in a short period of time, it may be difficult to determine which one is responsible [<a href="#rid42">42</a>]. Commonly used drugs associated with DITP in hospitalized patients are <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, and <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>. In these challenging situations, it may be necessary to stop all possible drugs. If one drug is strongly implicated and the others are not, it may be reasonable to discontinue only the strongly implicated drug [<a href="#rid72">72</a>]. Ultimately, the choice between stopping all, some, or one drug is based on clinical judgement that balances the likelihood for each drug and the risks to the patient of drug discontinuation for each drug. </p><p></p><p class="bulletIndent1">In addition to the drugs listed above (see <a class="local">'Commonly implicated drugs'</a> above) and in the table  (<a class="graphic graphic_table graphicRef73618" href="/z/d/graphic/73618.html" rel="external">table 1</a>), systematic reviews of evidence for a causal relationship of drugs with thrombocytopenia are periodically updated [<a href="#rid27">27,73-78</a>].</p><p></p><p class="headingAnchor" id="H557598845"><span class="h2">Role of drug-dependent platelet antibody testing</span><span class="headingEndMark"> — </span>We consider testing for drug-dependent antiplatelet antibodies to be an important component of the evaluation for DITP. This testing is especially helpful for distinguishing among drugs in a patient for whom one of several drugs may be responsible, for identifying (and reporting) a new association that has not previously been reported, and in cases where re-exposure to a drug is likely. A positive test would result in the need for lifelong drug avoidance. </p><p>Testing is generally only done in reference laboratories (such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.versiti.org%2Fdiagnostic-labs-test-menu%2Fcatalog%2Fdrug-dependent-platelet-antibody&amp;token=jW6gknNOJrmSXkbM7%2FvEexcowuT3XyRv2VXg744mkjWmETeBlLQ%2FTmByNA8D05kIvUOMglgZ26jAtmHUY7GFT7Hx2f4iMk5qhA10fgo0RaOm3Y3dL692YBN%2B9tlL9%2B9R&amp;TOPIC_ID=6674" target="_blank">Blood center of Wisconsin</a>). Flow cytometry-based assays to identify drug-dependent platelet antibodies are most commonly used  (<a class="graphic graphic_figure graphicRef65492" href="/z/d/graphic/65492.html" rel="external">figure 2</a>) [<a href="#rid1">1,10,30,79-81</a>]. The cost is relatively low (similar to the cost of HIT antibody testing), and confirmation of the presence of a drug-dependent antiplatelet antibody has important implications for future drug avoidance and for adverse event reporting. (See <a class="local">'Management'</a> below.)</p><p>Although testing for drug-dependent antibodies is helpful when the diagnosis is unclear, this testing is not required for establishing the diagnosis when the suspected drug has a well-established role in causing DITP. </p><p>DITP remains a clinical diagnosis (see <a class="local">'Approach'</a> above). The antibody testing can be performed after the drug has been discontinued as confirmation, because drug-dependent antiplatelet antibodies persist for many years, but the highest yield would be to test during the episode of acute thrombocytopenia. Unlike DITP testing, testing for heparin-induced thrombocytopenia is widely available with a fast turnaround time, and detectable antibodies generally do not persist beyond 100 days [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p>Importantly, antibody testing, when used, should not delay drug discontinuation in a patient with clinically suspected DITP.</p><p>While a positive test for drug-dependent platelet antibodies confirms the diagnosis of DITP, a negative test does not rule it out. The low sensitivity of DITP testing can be explained by the need for specialized test methods including the use of the drug in the platelet washing steps and the possibility that drug metabolites rather than the drug itself can be the trigger  (<a class="graphic graphic_figure graphicRef65492" href="/z/d/graphic/65492.html" rel="external">figure 2</a>) [<a href="#rid79">79,80</a>]. Negative results are sometimes seen in patients with a strong clinical likelihood of DITP [<a href="#rid10">10,23,83,84</a>]. </p><p>Additionally, the drug may cause thrombocytopenia by a mechanism other than DITP such as bone marrow suppression (as with <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>) or primary ITP (as with <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>).</p><p>As noted above, the clinician must often use clinical judgment to decide whether to discontinue therapy with one or more of the patient's medications. (See <a class="local">'Decide which drug(s) to stop'</a> above.)</p><p class="headingAnchor" id="H2851288729"><span class="h2">Role of drug rechallenge</span><span class="headingEndMark"> — </span>We rarely use drug rechallenge intentionally due to the risks of recurrent thrombocytopenia. However, in some cases rechallenge may occur inadvertently, or the drug-induced etiology may only be identified in retrospect. In such cases, recurrence of thrombocytopenia upon re-administration of the drug (or other substance) provides strong evidence that the drug is responsible for thrombocytopenia in that patient. In the majority of patients, we use clinical assessment and/or testing for drug-dependent antibodies rather than rechallenge to establish the diagnosis of DITP. (See <a class="local">'Role of drug-dependent platelet antibody testing'</a> above.)</p><p>Examples of the potentially deleterious effects of rechallenge include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe and symptomatic thrombocytopenia has been described in reports of rechallenges when the implicated agent was a food such as walnuts or herbal preparation [<a href="#rid63">63,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe thrombocytopenia following rechallenge with a GP IIb/IIIa inhibitor was illustrated in a prospective review of 550 patients who received a second or third dose of abciximab at least seven days after a first treatment [<a href="#rid85">85</a>]. Thrombocytopenia developed in 4.6 percent, was severe (platelet count &lt;20,000/microL) in 2.4 percent, and occurred after hospital discharge in 0.4 percent. In a second report, the incidence of recurrent severe thrombocytopenia was 4 percent in patients re-exposed to abciximab, but this increased to 12 percent if the interval between exposures was ≤2 weeks [<a href="#rid86">86</a>].</p><p></p><p>In some cases, thrombocytopenia may develop in association with a type of medication that the patient needs (eg, an antibiotic for bacterial infection). We prefer to substitute an agent of another class if possible, to avoid potential antigenic cross-reactivity with the implicated drug. If an alternative class of medications does not exist, it may be possible to give an agent from the same class without causing thrombocytopenia, but good data to support this practice are lacking for most agents. Among the different GP IIb/IIIa inhibitors, the risk of antibody cross-reactivity is thought to be on the order of 15 percent. (See <a class="local">'Mechanisms of DITP'</a> above.)</p><p>Although we avoid rechallenge if at all possible, there may be rare cases in which drug-dependent antibody testing did not identify an implicated drug (or the patient was told the results were negative but documentation is lacking) and the patient is likely to be re-exposed to a possibly implicated drug (eg, history of thrombocytopenia after <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>). In this setting, drug readministration should be done under supervised conditions with close observation of the platelet count and starting with very low doses of the drug. Recurrence of thrombocytopenia on rechallenge provides strong evidence for avoidance of the drug or substance for life.</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of DITP includes a number of other causes of thrombocytopenia  (<a class="graphic graphic_table graphicRef77063" href="/z/d/graphic/77063.html" rel="external">table 2</a>), which are discussed briefly above (see <a class="local">'Exclude other causes of thrombocytopenia'</a> above) and in more detail in separate topic reviews. The most commonly seen alternative diagnoses are primary immune thrombocytopenia (ITP) in asymptomatic outpatients and sepsis and/or disseminated intravascular coagulation (DIC) in acutely ill patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary ITP</strong> – Primary immune thrombocytopenia (ITP) is an autoimmune condition in which antiplatelet antibodies cause thrombocytopenia that may be transient in children and may last for months to years to indefinitely in adults. Like DITP, patients with primary ITP typically present as otherwise healthy individuals who develop new onset thrombocytopenia without an obvious cause. Unlike DITP, primary ITP does not resolve when a drug is discontinued. The distinction between DITP and primary ITP is critical in order to avoid unnecessary treatment directed at ITP in a patient with a drug-induced etiology [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sepsis/DIC</strong> – Sepsis and disseminated intravascular coagulation (DIC) cause thrombocytopenia, but the patient is very ill with fever and leukocytosis. DIC may also accompany an underlying malignancy. Like individuals with drug-induced thrombocytopenia, patients with sepsis and/or DIC may be receiving multiple medications, some of which may be on the list of drugs that can cause thrombocytopenia; and they may have bleeding. Unlike patients with drug-induced thrombocytopenia, those with sepsis and/or DIC have other laboratory abnormalities indicative of a systemic infection (leukocytosis or neutropenia) and ongoing coagulation (prolonged PT and PTT, low fibrinogen, elevated D-dimer). (See  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transfusion purpura</strong> – Post-transfusion purpura (PTP) is a rare complication that may occur after transfusion of any platelet-containing blood product (red blood cells, platelets, or granulocytes). Like drug-induced thrombocytopenia, PTP may present as new onset severe thrombocytopenia in a patient who has been hospitalized or acutely ill. Unlike drug-induced thrombocytopenia, PTP requires a history of transfusion in the previous 7 to 10 days, and PTP responds to immunosuppressive therapy (typically, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [IVIG]). (See  <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Post-transfusion purpura'</a>.)</p><p></p><p>More extensive discussions of these and other causes of thrombocytopenia are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology"</a> and  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children"</a> and  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1269052805"><span class="h2">Drug discontinuation</span><span class="headingEndMark"> — </span>Drug discontinuation is essential in patients with suspected DITP, regardless of clinical presentation. An alternative medication can almost always be substituted if needed. The decision about which drug(s) to discontinue depends on clinical judgement regarding the degree of suspicion for DITP and the decision regarding which drug(s) are the most likely candidates. (See <a class="local">'Decide which drug(s) to stop'</a> above.)</p><p class="headingAnchor" id="H3377177166"><span class="h2">Decision to hospitalize</span><span class="headingEndMark"> — </span>For patients with DITP, the platelet count will recover promptly following withdrawal of the offending agent. The need for hospitalization is stratified according to the severity of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a healthy outpatient who has severe thrombocytopenia but no bleeding or only minor purpura, hospitalization may not be required as long as there is no evidence for an alternative diagnosis such as drug-induced thrombotic microangiopathy (DITMA), the patient is reliably able to communicate, and they are able to have daily platelet counts measured.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is any bleeding more than minor purpura (eg, if there is epistaxis, heavy menstrual bleeding, or other bleeding), the patient should be hospitalized for close observation. Platelet transfusions are also appropriate and should be given to control clinically important bleeding. Steroids are often given because the distinction of DITP from ITP is often initially unclear. (See <a class="local">'Treatment of bleeding/severe thrombocytopenia'</a> below.)</p><p></p><p class="headingAnchor" id="H3324455803"><span class="h2">Treatment of bleeding/severe thrombocytopenia</span></p><p class="headingAnchor" id="H1206454093"><span class="h3">Risk of bleeding and mortality</span><span class="headingEndMark"> — </span>The likelihood of clinical bleeding depends on a number of factors including comorbidities, other medications, and platelet count. Bleeding risk is greater with DITP than with primary ITP [<a href="#rid46">46</a>]. Bleeding risk generally increases with platelet counts below 40,000 to 50,000/microL, but there is not a strong linear correlation between platelet count and bleeding risk [<a href="#rid28">28</a>]. The risk of severe bleeding, including intracranial hemorrhage, may be higher in DITP than in primary ITP, possibly because the onset of severe thrombocytopenia occurs rapidly.</p><p class="bulletIndent1"><span class="glyph">●</span>In a 1997 series of 309 patients with drug-induced thrombocytopenia, more serious bleeding such as gastrointestinal and intracranial bleeding was seen in 12 and 3 percent, respectively [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 1998 review of 247 patients, 23 (9 percent) had serious bleeding and two patients (1 percent) had fatal bleeding, both in association with <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> exposure [<a href="#rid27">27</a>]. </p><p></p><p>Drug-induced thrombocytopenia has been associated with increased mortality in other series, especially in hospitalized patients; however, it may be challenging to distinguish association from causality [<a href="#rid87">87</a>]. </p><p class="headingAnchor" id="H2406031483"><span class="h3">Life-threatening bleeding: platelet transfusions</span><span class="headingEndMark"> — </span>Treatment of bleeding and/or severe thrombocytopenia requires close communication among consulting specialists. For major or life-threatening bleeding, platelet transfusions should be administered without delay. Glucocorticoids and/or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) may be used because drug-induced thrombocytopenia initially cannot be distinguished from immune thrombocytopenia (ITP).</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with clinically important bleeding and/or platelet count &lt;10,000/microL should receive platelet transfusions [<a href="#rid2">2</a>]. Higher thresholds for platelet transfusion may apply in certain settings (eg, fever, infection, GP IIb/IIIa or other antithrombotic agent). <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may also be administered if platelet transfusions are ineffective in stopping bleeding [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Actively bleeding patient'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a presumptive diagnosis of DITP due to a GP IIb/IIIa inhibitor who have severe bleeding or require an emergency invasive procedure, platelet transfusions are often given even if the thrombocytopenia is not severe, because these agents interfere with platelet function. Typically, heparin and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are also discontinued and heparin anticoagulation is reversed with <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">protamine sulfate</a>. One report of four patients with DITP due to abciximab found a rapid platelet count response to platelet transfusions, and no apparent benefit from <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Reversal'</a>.)</p><p></p><p class="headingAnchor" id="H610630804"><span class="h3">Role of IVIG and glucocorticoids</span></p><p class="bulletIndent1"><span class="glyph">●</span>For severe or life-threatening bleeding, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may also be given, especially if the diagnosis of DITP versus primary ITP has not been resolved. Management of patients with possible primary ITP and severe bleeding is discussed separately. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When bleeding other than petechiae/purpura is present but not severe, glucocorticoids are often given because initially DITP may be indistinguishable from primary ITP. The role of platelet transfusion in the setting of severe but not life-threatening bleeding is individualized. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Choice of glucocorticoid and dosing'</a>.)</p><p></p><p class="headingAnchor" id="H2126658195"><span class="h2">Platelet count recovery/monitoring</span><span class="headingEndMark"> — </span>DITP is reversible upon drug discontinuation, and documentation of platelet count recovery is important in confirming the diagnosis. The platelet count is expected to begin increasing within one to two days of drug discontinuation and return to the patient’s normal range in a week [<a href="#rid42">42</a>]. In retrospective series that have reported on the time to platelet count recovery, typical times to platelet recovery are in the range of seven to eight days [<a href="#rid27">27,28,42</a>].</p><p>The frequency of monitoring depends on the severity of thrombocytopenia and patient’s clinical condition (eg, presence of bleeding). For healthy outpatients with a finding of drug-induced thrombocytopenia prompted by petechiae/bruising without other significant bleeding, it may be appropriate to recheck the platelet count daily to be sure that the platelet count is recovering, and then a week later to be sure that the platelet count has recovered to normal. It is appropriate to see the patient for a follow-up evaluation in another month, to be sure that the platelet count has remained normal. It is also important to review the remainder of the complete blood count (CBC), especially in patients with slow recovery, to identify any other abnormality that might develop.</p><p>However, some drugs (or drug metabolites) remain in the circulation for longer periods, and drug elimination may be further reduced in individuals with reduced metabolism due to renal or hepatic insufficiency. Platelet count recovery may be slower in these settings.</p><p>Additional rare agents have been reported to be associated with prolonged thrombocytopenia that is more similar to primary ITP.</p><p class="bulletIndent1"><span class="glyph">●</span>Vaccine for measles, mumps, and rubella (MMR) have been associated with the development of ITP [<a href="#rid18">18</a>]. Similarly acute and sometimes severe ITP has been described following administration of coronavirus disease 2019 (COVID-19) vaccines [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar syndrome has been reported with <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, a monoclonal antibody directed against the lymphocyte surface marker CD52 [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients receiving <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a> have more prolonged duration of thrombocytopenia, perhaps due to direct megakaryocyte impairment by eptifibatide-induced antibodies [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When gold salts were commonly used for the treatment of rheumatoid arthritis, they could be associated with prolonged thrombocytopenia. Gold-induced thrombocytopenia may resemble primary ITP more than DITP, in that it has a propensity to develop long after therapy has been discontinued, to occur more often in patients with HLA-DR3, to be associated with drug-independent antibodies, and to respond to immunosuppressive agents such as glucocorticoids [<a href="#rid90">90-92</a>]. </p><p></p><p>Once it has become established that the platelet count remains normal, there is no need to perform additional platelet counts unless the patient receives the drug again or develops stigmata of bleeding.</p><p>In contrast to platelet count monitoring after DITP is diagnosed, the role of platelet count monitoring to detect new onset DITP with drugs such as GP IIb/IIIa inhibitors or heparin is discussed separately. (See <a class="local">'GP IIb/IIIa inhibitors'</a> above and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Platelet count monitoring'</a>.)</p><p class="headingAnchor" id="H32224326"><span class="h2">Documentation/reporting</span><span class="headingEndMark"> — </span>In patients with DITP it is essential to document the association (with the name of the drug) in the patient's medical record, and to ensure that the patient has this information available, in order to avoid future inadvertent administration of a causative drug. This is especially true when a single agent is strongly implicated by clinical criteria  (<a class="graphic graphic_table graphicRef76822" href="/z/d/graphic/76822.html" rel="external">table 4</a>). Since drug-dependent, platelet-reactive antibodies can persist for many years and cause acute, severe thrombocytopenia with a repeat exposure as long as 10 years after the previous exposure, the patient should be informed that the drug should be avoided indefinitely and should be advised to wear a medical alert bracelet or carry a wallet card indicating this fact.</p><p>Reporting of drug-induced thrombocytopenia to the medical community is important for making other clinicians aware of the possibility of thrombocytopenia as an adverse effect of a drug not previously known to cause thrombocytopenia.</p><p class="bulletIndent1"><span class="glyph">●</span>All occurrences of DITP in the United States should be reported on the US Food and Drug Administration's MedWatch website (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;token=xvyaImDcLZQw%2FKZaoXWwxUDhBq6SPMBQbzrmFLdvw6uLInTYq0WEZZE23nYfEJdpji3bziSW87ksfkpGSKeZ%2FC4BVOKV%2FWdosDZdfOoBdep7W5s6oZowZkx4dccnetNU&amp;TOPIC_ID=6674" target="_blank">http://www.fda.gov/Safety/MedWatch/default.htm</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a drug has not been previously reported as a cause of thrombocytopenia with definite or probable clinical evidence  (<a class="graphic graphic_table graphicRef76822" href="/z/d/graphic/76822.html" rel="external">table 4</a>) (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ouhsc.edu%2Fplatelets&amp;token=ZiLQ8BkqDz0AL92cCSR%2BAYrPaP%2Fj2cBcvuhigIEBe4reUe5gp2QPsBE7BNRIM9z%2F&amp;TOPIC_ID=6674" target="_blank">www.ouhsc.edu/platelets</a>), it is important to document this observation with a published case report [<a href="#rid11">11</a>]. Testing for drug-dependent antibodies should be included in the published case report if not previously documented for that drug.</p><p></p><p class="headingAnchor" id="H2538231005"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105473.html" rel="external">"Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Drug-induced immune thrombocytopenia (DITP) refers to thrombocytopenia caused by drug-dependent, antibody-mediated platelet destruction. DITP is a form of secondary ITP. The "drug" may be a prescribed or over-the-counter medication, a metabolite, an herbal supplement, a food or beverage  (<a class="graphic graphic_table graphicRef60296" href="/z/d/graphic/60296.html" rel="external">table 3</a>), or other substance. An apparently "naturally occurring" antibody, a primary ITP-like syndrome, and/or megakaryocyte destruction may be involved. (See <a class="local">'Terminology'</a> above and <a class="local">'Mechanisms of DITP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>List of drugs</strong> – Drugs commonly implicated in DITP are listed in the table  (<a class="graphic graphic_table graphicRef73618" href="/z/d/graphic/73618.html" rel="external">table 1</a>). Heparin-induced thrombocytopenia (HIT) can cause mild to moderate thrombocytopenia and potentially fatal arterial and venous thromboses. Glycoprotein (GP) IIb/IIIa inhibitors can cause true DITP and pseudothrombocytopenia. (See <a class="local">'List of drugs'</a> above and <a class="local">'Heparins'</a> above and <a class="local">'GP IIb/IIIa inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and presentation</strong> – The overall risk of DITP from any new drug is rare. Patients typically present within two weeks of exposure with severe thrombocytopenia (platelet count &lt;20,000/microL) and/or bleeding. (See <a class="local">'Incidence'</a> above and <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – DITP is a clinical diagnosis made by excluding other causes of thrombocytopenia and documenting resolution of thrombocytopenia upon drug discontinuation. Laboratory testing for drug dependent antiplatelet antibodies is often helpful but not required. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes other causes of thrombocytopenia  (<a class="graphic graphic_table graphicRef77063" href="/z/d/graphic/77063.html" rel="external">table 2</a>). In asymptomatic outpatients, primary ITP is the other main cause. In acutely ill patients, sepsis and/or disseminated intravascular coagulation (DIC) are common causes of thrombocytopenia. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Drug discontinuation is essential in patients with suspected DITP; if needed, a substitute medication can almost always be provided. The need for hospitalization is stratified according to the severity of findings. (See <a class="local">'Drug discontinuation'</a> above and <a class="local">'Decision to hospitalize'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of bleeding</strong> – For clinically important bleeding, platelet transfusions should be administered without delay. Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) may also be given if bleeding is severe and primary ITP is a possible diagnosis. When bleeding other than petechiae/purpura is present but not severe, glucocorticoids are often given. (See <a class="local">'Treatment of bleeding/severe thrombocytopenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recovery</strong> – The platelet count will increase, often beginning one to two days after drug discontinuation, with return to the patient's normal range in a week, unless drug metabolism and elimination are impaired by impaired kidney or liver function. All drug-induced thrombocytopenia should be communicated to the patient and documented in the medical record. Publication of a case report is encouraged for drugs not previously known to cause DITP. In the United States a report should be filed on the US Food and Drug Administration's <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;token=xvyaImDcLZQw%2FKZaoXWwxUDhBq6SPMBQbzrmFLdvw6uLInTYq0WEZZE23nYfEJdpji3bziSW87ksfkpGSKeZ%2FC4BVOKV%2FWdosDZdfOoBdep7W5s6oZowZkx4dccnetNU&amp;TOPIC_ID=6674" target="_blank">MedWatch website</a>. (See <a class="local">'Platelet count recovery/monitoring'</a> above and <a class="local">'Documentation/reporting'</a> above.)</p><p></p><p class="headingAnchor" id="H3081389932"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James N George, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7:911.</a></li><li><a class="nounderline abstract_t">Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580.</a></li><li><a class="nounderline abstract_t">Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27:137.</a></li><li><a class="nounderline abstract_t">Greinacher A, Fuerll B, Zinke H, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114:1250.</a></li><li><a class="nounderline abstract_t">Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 2006; 108:922.</a></li><li><a class="nounderline abstract_t">Zhu J, Zhu J, Bougie DW, et al. Structural basis for quinine-dependent antibody binding to platelet integrin αIIbβ3. Blood 2015; 126:2138.</a></li><li><a class="nounderline abstract_t">Bougie DW, Peterson J, Rasmussen M, Aster RH. Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa. Blood 2015; 126:2146.</a></li><li><a class="nounderline abstract_t">George JN, Morton JM, Liles NW, Nester CM. After the Party's Over. N Engl J Med 2017; 376:74.</a></li><li><a class="nounderline abstract_t">Burgess JK, Lopez JA, Berndt MC, et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998; 92:2366.</a></li><li><a class="nounderline abstract_t">Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84:176.</a></li><li><a class="nounderline abstract_t">Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116:2127.</a></li><li><a class="nounderline abstract_t">Christie DJ, Weber RW, Mullen PC, et al. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. J Lab Clin Med 1984; 104:730.</a></li><li><a class="nounderline abstract_t">Curtis BR, Kaliszewski J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81:193.</a></li><li><a class="nounderline abstract_t">Mirtsching BC, George JN, Aster RH, Curtis BR. Irinotecan-induced immune thrombocytopenia. Am J Med Sci 2014; 347:167.</a></li><li><a class="nounderline abstract_t">Curtis BR, Hsu YS, Podoltsev N, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood 2018; 131:1486.</a></li><li><a class="nounderline abstract_t">Shiuan E, Beckermann KE, Ozgun A, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017; 5:8.</a></li><li><a class="nounderline abstract_t">Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011; 118:6299.</a></li><li><a class="nounderline abstract_t">Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623.</a></li><li><a class="nounderline abstract_t">Lee EJ, Beltrami-Moreira M, Al-Samkari H, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood 2022; 139:1564.</a></li><li><a class="nounderline abstract_t">Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis 2013; 13:66.</a></li><li><a class="nounderline abstract_t">Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723.</a></li><li><a class="nounderline abstract_t">Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009; 15:2488.</a></li><li><a class="nounderline abstract_t">Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998; 92:2359.</a></li><li><a class="nounderline abstract_t">Burgess JK, Lopez JA, Gaudry LE, Chong BH. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 2000; 95:1988.</a></li><li><a class="nounderline abstract_t">Pereira J, Hidalgo P, Ocqueteau M, et al. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol 2000; 110:907.</a></li><li><a class="nounderline abstract_t">Kroll H, Sun QH, Santoso S. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood 2000; 96:1409.</a></li><li><a class="nounderline abstract_t">George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997; 52:183.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54:701.</a></li><li><a class="nounderline abstract_t">Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356:904.</a></li><li><a class="nounderline abstract_t">Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82:2714.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard U, Andersen M, Hansen PB. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996; 239:509.</a></li><li><a class="nounderline abstract_t">ten Berg MJ, Huisman A, Souverein PC, et al. Drug-induced thrombocytopenia: a population study. Drug Saf 2006; 29:713.</a></li><li><a class="nounderline abstract_t">Patel N, VanDeWall H, Tristani L, et al. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother 2012; 67:727.</a></li><li><a class="nounderline abstract_t">Nusrat S, Borogovac A, George JN, et al. Drug (vaccine)-induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features. Am J Hematol 2022; 97:E162.</a></li><li class="breakAll">Search on "Drug-induced thrombocytopenia". www.ouhsc.edu/platelets (Accessed on February 06, 2016).</li><li><a class="nounderline abstract_t">Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost 2013; 11:169.</a></li><li><a class="nounderline abstract_t">van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27:1243.</a></li><li><a class="nounderline abstract_t">Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology 2014; 30:55.</a></li><li><a class="nounderline abstract_t">Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28:1871.</a></li><li><a class="nounderline abstract_t">Reese JA, Nguyen LP, Buchanan GR, et al. Drug-induced thrombocytopenia in children. Pediatr Blood Cancer 2013; 60:1975.</a></li><li><a class="nounderline abstract_t">Rousan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol 2010; 85:71.</a></li><li><a class="nounderline abstract_t">Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2:985.</a></li><li><a class="nounderline abstract_t">O'Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol 2007; 82:1122.</a></li><li><a class="nounderline abstract_t">George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009; :153.</a></li><li><a class="nounderline abstract_t">Warkentin TE. Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis. N Engl J Med 2007; 356:891.</a></li><li><a class="nounderline abstract_t">Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000; 9:175.</a></li><li><a class="nounderline abstract_t">Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006; 97:426.</a></li><li><a class="nounderline abstract_t">Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997; 95:809.</a></li><li><a class="nounderline abstract_t">Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32:311.</a></li><li><a class="nounderline abstract_t">Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000; 140:206.</a></li><li><a class="nounderline abstract_t">Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109:2203.</a></li><li><a class="nounderline abstract_t">Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36:75.</a></li><li><a class="nounderline abstract_t">Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100:2071.</a></li><li><a class="nounderline abstract_t">Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99:3540.</a></li><li><a class="nounderline abstract_t">Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008; 111:1234.</a></li><li><a class="nounderline abstract_t">Bougie DW, Rasmussen M, Zhu J, Aster RH. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood 2012; 119:6317.</a></li><li><a class="nounderline abstract_t">Gao C, Boylan B, Bougie D, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 2009; 119:504.</a></li><li><a class="nounderline abstract_t">Curtis BR, Swyers J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99:2054.</a></li><li><a class="nounderline abstract_t">Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436.</a></li><li><a class="nounderline abstract_t">Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498.</a></li><li><a class="nounderline abstract_t">Royer DJ, George JN, Terrell DR. Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol 2010; 84:421.</a></li><li><a class="nounderline abstract_t">Azuno Y, Yaga K, Sasayama T, Kimoto K. Thrombocytopenia induced by Jui, a traditional Chinese herbal medicine. Lancet 1999; 354:304.</a></li><li><a class="nounderline abstract_t">Ohmori T, Nishii K, Hagihara A, et al. Acute thrombocytopenia induced by jui, a traditional herbal medicine. J Thromb Haemost 2004; 2:1479.</a></li><li><a class="nounderline abstract_t">Liles NW, Page EE, Liles AL, et al. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol 2016; 91:461.</a></li><li><a class="nounderline abstract_t">Arnold J, Ouwehand WH, Smith GA, Cohen H. A young woman with petechiae. Lancet 1998; 352:618.</a></li><li><a class="nounderline abstract_t">Achterbergh R, Vermeer HJ, Curtis BR, et al. Thrombocytopenia in a nutshell. Lancet 2012; 379:776.</a></li><li><a class="nounderline abstract_t">Kojouri K, Perdue JJ, Medina PJ, George JN. Occult quinine-induced thrombocytopenia. J Okla State Med Assoc 2000; 93:519.</a></li><li><a class="nounderline abstract_t">Reddy JC, Shuman MA, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med 2004; 164:218.</a></li><li><a class="nounderline abstract_t">Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122:966.</a></li><li class="breakAll">http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm350239.pdf.</li><li><a class="nounderline abstract_t">Greinacher A, Selleng S. How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood 2016; 128:3032.</a></li><li class="breakAll">http://www.ouhsc.edu/platelets/ditp.html.</li><li><a class="nounderline abstract_t">Al-Nouri ZL, George JN. Drug-induced thrombocytopenia: an updated systematic review, 2012. Drug Saf 2012; 35:693.</a></li><li><a class="nounderline abstract_t">Nguyen L, Reese J, George JN. Drug-induced thrombocytopenia: an updated systematic review, 2010. Drug Saf 2011; 34:437.</a></li><li><a class="nounderline abstract_t">Swisher KK, Li X, Vesely SK, George JN. Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf 2009; 32:85.</a></li><li><a class="nounderline abstract_t">Li X, Swisher KK, Vesely SK, George JN. Drug-induced thrombocytopenia: an updated systematic review, 2006. Drug Saf 2007; 30:185.</a></li><li><a class="nounderline abstract_t">Rizvi MA, Kojouri K, George JN. Drug-induced thrombocytopenia: an updated systematic review. Ann Intern Med 2001; 134:346.</a></li><li><a class="nounderline abstract_t">Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001; 97:3846.</a></li><li><a class="nounderline abstract_t">Bougie DW, Benito AI, Sanchez-Abarca LI, et al. Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood 2007; 109:3608.</a></li><li><a class="nounderline abstract_t">Scognamiglio F, Corso C, Madeo D, et al. Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases. Am J Hematol 2008; 83:326.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286.</a></li><li><a class="nounderline abstract_t">Leach MF, Cooper LK, AuBuchon JP. Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays. Br J Haematol 1997; 97:755.</a></li><li><a class="nounderline abstract_t">Nieminen U, Kekomäki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol 1992; 80:77.</a></li><li><a class="nounderline abstract_t">Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104:870.</a></li><li><a class="nounderline abstract_t">Madan M, Kereiakes DJ, Hermiller JB, et al. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol 2000; 85:435.</a></li><li><a class="nounderline abstract_t">McMahon CM, Cuker A. Hospital-acquired thrombocytopenia. Hosp Pract (1995) 2014; 42:142.</a></li><li><a class="nounderline abstract_t">Ray JB, Brereton WF, Nullet FR. Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia. DICP 1990; 24:693.</a></li><li><a class="nounderline abstract_t">Kereiakes DJ, Essell JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78:1161.</a></li><li><a class="nounderline abstract_t">Coblyn JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95:178.</a></li><li><a class="nounderline abstract_t">Adachi JD, Bensen WG, Kassam Y, et al. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987; 16:287.</a></li><li><a class="nounderline abstract_t">Garner SF, Campbell K, Metcalfe P, et al. Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 2002; 100:344.</a></li></ol></div><div id="topicVersionRevision">Topic 6674 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344362" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687133" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845922" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Approach to the diagnosis and management of drug-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429867" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861345" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282540" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structural basis for quinine-dependent antibody binding to platelet integrinαIIbβ3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26353910" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052232" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : After the Party's Over.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746776" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517207" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530792" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6491470" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493620" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472819" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Irinotecan-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29439950" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28239462" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21960587" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097358" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587251" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23379510" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12121967" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hematologic effects of linezolid: summary of clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746775" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706865" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054081" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942385" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867731" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Drug-induced thrombocytopenia: a systematic review of published case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9218924" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9923571" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329697" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vancomycin-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8219224" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute thrombocytopenic purpura in relation to the use of drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8656144" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872245" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Drug-induced thrombocytopenia: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22174041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092624" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Drug (vaccine)-induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092624" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Drug (vaccine)-induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121994" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15588119" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247620" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890635" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thrombocytopenia and prognosis in intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24038783" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Drug-induced thrombocytopenia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19802882" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140135" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665503" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immune thrombocytopenia from vancomycin in orthopedic cement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008194" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329695" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613999" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054735" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708455" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10925331" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117843" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898416" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200368" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986205" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959856" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490676" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers ofαIIb/β3 integrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197137" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877279" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9705684" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599104" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525061" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440313" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thrombocytopenia induced by Jui, a traditional Chinese herbal medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304064" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acute thrombocytopenia induced by jui, a traditional herbal medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822544" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Diversity and severity of adverse reactions to quinine: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746024" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A young woman with petechiae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22364760" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thrombocytopenia in a nutshell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126885" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Occult quinine-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744847" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Quinine/quinidine-induced thrombocytopenia: a great imitator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956768" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956768" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034871" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : How I evaluate and treat thrombocytopenia in the intensive care unit patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034871" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : How I evaluate and treat thrombocytopenia in the intensive care unit patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22762135" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Drug-induced thrombocytopenia: an updated systematic review, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21661269" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Drug-induced thrombocytopenia: an updated systematic review, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132808" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Drug-induced thrombocytopenia: an updated systematic review, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253882" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Drug-induced thrombocytopenia: an updated systematic review, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182857" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Drug-induced thrombocytopenia: an updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389025" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409346" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18027833" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320387" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Temporal aspects of heparin-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217173" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536813" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11514371" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Abciximab readministration: results of the ReoPro Readministration Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728946" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of abciximab readministration in coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25502138" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hospital-acquired thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1695793" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914883" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6942668" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110956" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Gold induced thrombocytopenia: 12 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070047" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
